OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer

Summary

This Ⅱ study evaluates the safety and efficacy of intratumoral injection of OH2 in locally advanced or metastatic bladder cancer. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.

Timeline

Start

2022-05-25

Primary completion

2024-10-28

Completion

2024-10-28

Drugs

Indications